Veterinary Vaccine Conference 2017 logo

From livestock to companion, gain crucial insights into the emerging infections and new technologies changing the landscape

ABOUT THE
VETERINARY VACCINE CONFERENCE

 

With the animal vaccines market predicted to be worth $8.6 billion by 2018, can you really afford not to be a core service provider for these manufacturers?

An increased focus on zoonotic infectious diseases and more attention towards the economic impact of disease in livestock of economic importance, make it clear why veterinary vaccines are coming into the limelight.

This event will provide a platform for you to showcase how you are moving veterinary vaccine development methods forward, from technology to regulation and manufacture.

SCROLL DOWN FOR THE 2017 AGENDA

 

2017 AGENDA

Veterinary, Tuesday 11 April 2017

Gareth Harris
Veterinary
09:10

Regulatory pathways to enable the licensing of veterinary vaccines

 
  • Addressing common regulatory pitfalls in the commercialization of new technologies and perspectives on the approaches to successful registration
  • Rapid licensing for emerging diseases
  • Perspectives on APHIS Memorandum 800.213 memo for licensing platforms
Dr Bernard Vallat
Veterinary
09:40

Examining legislation on veterinary vaccination and global practices for animal vaccination

 
  • Redefining the role of public sector and private sector veterinarians and technicians
  • Highlighting models of synergies between public and private sector veterinarians for animal vaccination
  • Epizootic diseases vaccination campaigns
  • Discussing mandates provided by the public sector to private veterinarians for vaccination campaigns
Dr Nesya Goris
Veterinary
10:10

Enabling the One Health concept through enhanced communication and collaboration between human and animal health

10:40

Networking coffee break

Dr Nathalie Garcon
Veterinary
11:40

Alleviating disparities between animal and human adjuvanted vaccines

 
  • One health perspective on how to exploit human and veterinary vaccines for therapeutic and preventative treatment across all species
  • Measuring efficacy, toxicity and correlates of protection
  • The future of adjuvants in preclinical and clinical development
Dr Mahesh Kumar
Veterinary
12:10

Maternal immunity - Its role in vaccination and animal health

Dr Egbert Mundt
Veterinary
12:40

Success story for alternative influenza platforms: Update on avian influenza vaccines

 
  • Developing poultry vaccines using insect cells
  • Baculovirus system in insect cells for avian influenza in poultry
  • Challenges faced and lessons learnt for future developments
13:10

Networking Lunch & Poster Session

Dr John El-Attrache
Veterinary
14:40

Utilization of Next Generation Sequencing for selection of vaccine candidates for production animals

 
  • Analyzing full genomic sequences of bacteria isolates
  • Analyzing recombinant HVT vectors
  • Identification of subpopulations
]
Douglas Gladue
Veterinary
15:10

Rational approaches to develop a live attenuated vaccine for African swine fever

Dr Hanjo Hennemann
Veterinary
15:40

Yeast-based vaccines: Merging high efficacy, easy antigen combination and advantageous cost of goods

 
  • A novel subunit marker vaccine technology based on milk-yeast
  • New validation data for the technology and vaccines targeting both capsid and enveloped viruses
  • Save >90 % of the manufacturing costs, due to cost effective fermentation, using a single production run for combi vaccines and lacking the need to purify antigens
16:10

Networking coffee break

Dr Jens Gertow
Veterinary
16:40

ELISpot and FluoroSpot in veterinary vaccine research

 
  • T-cell ELISpot assays and B-cell ELISpot assays in veterinary vaccine research
  • Novel potential of T and B-cell FluoroSpot assays in veterinary vaccine research
  • Why FluoroSpot and not intracellular cytokine staining and Flow cytometry?
Dr Luigi Aurisicchio
Veterinary
16:55

Genetic cancer vaccines for pets: Cutting-edge technologies with high translational potential for humans

 
  • How relevant are preclinical models for developing Cancer Vaccines
  • How to combine new Cancer Vaccines with existing therapies
  • How to achieve local and systemic Cancer control
  • Moving towards innovative products: lessons learnt
Dr Patrick Frayssinet
Veterinary
17:10

Developing a novel vaccine for therapeutic treatment of cancer in companion animals

 
  • Clinical data demonstrating the progress in adaptive immunotherapy for cancer in companion animals
  • Harnessing the ability of the immune system to eradicate cancer and sharing mode of mechanism
  • Lessons learnt from developing an innovative and patented immunotherapy method to treat cancer in companion animals
Veterinary
17:25

Meeting the need for innovative antigen expression systems

 
  • Reengineering expression systems to for improved vaccine development
  • Discussing feasibility of scale-up expression
Dr Cyril Gay
Veterinary
17:40

Vaccine research, trans-boundary diseases and the biodefence research programme

 
  • Control of highly specially-dangerous pathogens.
  • Developing vaccines engineered for the purpose of control and responding to disease outbreak
Mr Pascal Hudelet
Veterinary
18:10

Can we eradicate FMD? An industry perspective

 
  • Global overview of FMD vaccine use
  • Different epidemiological situations, different needs
  • Trends and future evolutions in the FMD vaccine world
  • How vaccine manufacturers contribute to FMD control and eradication
18:40

Chair’s closing remarks and close of congress day 2

18:45

Networking Drinks & Party

last published: 22/Mar/17 17:46

 

Veterinary, Wednesday 12 April 2017

Dr Yan Su
Veterinary
09:10

Investigational HDM-mLAMP-Vax DNA Vaccines for Canine Atopic Dermatitis Induce Robust Th1 Immune Responses in Mice and Dogs

 
  • Lysosomal Associated Membrane Protein (LAMP) is a major component of lysosomes
  • Investigational LAMP-Vax DNA vaccines are thought to utilize the intracellular localization of LAMP to bring antigens to MHC-II
  • LAMP-Vax DNA vaccines induce robust Th1 responses in multiple animal models of human allergic diseases
  • LAMP-Vax DNA vaccine was tested in a Phase I clinical study for Japanese red cedar for allergy and met its safety endpoints.
  • HDM-mLAMP-Vax vaccines encode two major allergens for Canine Atopic Dermatitis (CAD)
  • HDM-mLAMP-Vax vaccines induce Th1-skewed humoral and cellular immune response in mouse model for CAD
  • Immunogenicity of the HDM-mLAMP-Vax vaccines has been confirmed in dogs
Dr Anass Jawhari
Veterinary
09:40

New fragmentation and solubilization approaches toward bacterial and viral vaccines

  • A proprietary surfactant and detergent based approach consisting either on membrane splitting and/ or solubilization and stabilization
  • Presenting protection to commercialized influenza vaccines but using up to 30 times less antigens in one vaccine dose
  • Results from a bacterial vaccine against leptospirosis
Mr Timothy Miller
Veterinary
09:55

Effectively transitioning from vaccine research to commercial production.  The adjuvanted DNA vaccine example from Agrilabs.


 
Mr Vincent Munster
Veterinary
10:10

MERS-Cov vaccine for camels: Updates and new data

 
  • Discussing strategy from virus discovery to intervention
10:40

Networking coffee break

Dr GS Reddy
Veterinary
12:00

Eradicating Porcine Cysticercosis with a novel vaccine containing the TSol 18 protein

 
  • Global clinical trials demonstrating the efficacy of the vaccine in protecting pigs against T.solium
  • Recombinant vaccine containing TSol 18 protein licensed for commercial use for first time in the world
  • Exciting eradication potential and lessons learnt from development challenges faced
12:30

Networking Lunch & Poster Session

Dr Alan R. Hinman
13:40

The eradication of Polio: Have we succeeded?


-    Measuring and monitoring the success of eradication
-    End game and strategic plan
-    What’s next? Can we eradicate measles?
 
Professor Robert Daum
14:10

A call for greater consideration for the role of vaccines in national strategies to combat antibiotic-resistant bacteria


-    Recommendations from the National Vaccine Advisory Committee
-    Use of vaccines to prevent the infections that could or have developed AMR to antibiotics, in adjunction to antibiotic stewardship
-    Examples in Haemophilus influenza, Streptococcus, Staphylococcus aureus

 
Dr Gregory A. Poland
14:40

Panel: How much efficacy is enough? What are the implications of a vaccine no longer being a replacement technology but a companion technology?


-    The concept of partially protected vaccines like malaria, TB, NTDs where the clinical efficacy is no longer 85/90% but closer to 40% 
-    Future of vaccine development 
-    The combining drivers of technology and emerging diseases

More panelists to be announced shortly
15:30

Chair’s closing remarks and close of congress

last published: 22/Mar/17 17:46

 

 

Sign up for event updates

WHO ATTENDS?

  • Pharma
  • Biotech
  • National and International Government
  • Academics and Research Institutions ​

JOB TITLES

  • CEO / CSO / COO
  • CMO / Head of Scientific Affairs
  • Head of Poultry / Avian / Equine
  • Head of Infectious Disease
  • Head of R&D
  • Head of ManufacturingCEO / CSO / COO ​

 

 

WHO SPONSORS?

This is a key opportunity for specialists in vaccines for animal health from:​

  • CMOs
  • OEMs / Equipment Manufacturers
  • Platform Technology Providers
  • Biotechs
  • Big Pharma ​ ​